[1]雷雨,郑宏华,陈小红,等.胰高血糖素样肽-1治疗早期糖尿病视网膜病变的临床研究[J].眼科新进展,2018,38(7):656-659.[doi:10.13389/j.cnki.rao.2018.0154]
 LEI Yu,ZHENG Hong-Hua,CHEN Xiao-Hong,et al.Glucagon-like peptide-1(GLP-1) analogues for the treatment of early diabetic retinopathy[J].Recent Advances in Ophthalmology,2018,38(7):656-659.[doi:10.13389/j.cnki.rao.2018.0154]
点击复制

胰高血糖素样肽-1治疗早期糖尿病视网膜病变的临床研究/HTML
分享到:

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
38卷
期数:
2018年7期
页码:
656-659
栏目:
应用研究
出版日期:
2018-07-05

文章信息/Info

Title:
Glucagon-like peptide-1(GLP-1) analogues for the treatment of early diabetic retinopathy
作者:
雷雨郑宏华陈小红梅雪陈梅珠
350025 福建省福州市,福州总医院、厦门大学附属东方医院、福建医科大学福总临床医学院
Author(s):
LEI YuZHENG Hong-HuaCHEN Xiao-HongMEI XueCHEN Mei-Zhu
Fuzhou General Hospital,Dongfang Hospital Affiliated to Xiamen University,Clinical Medical College of Fujian Medical University,Fuzhou 350025,Fujian Province,China
关键词:
GLP-1类似物黄斑区视网膜厚度振荡电位糖尿病视网膜病变
Keywords:
glucagon-like peptide-1 analogsmacular retinal thicknessoscillatory potentialdiabetic retinopathy
分类号:
R774
DOI:
10.13389/j.cnki.rao.2018.0154
文献标志码:
A
摘要:
目的 观察胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)的类似物(利拉鲁肽)治疗轻、中度非增生期糖尿病视网膜病变(non-proliferative diabetic retinopathy,NPDR)的临床疗效。方法 收集我院内分泌科治疗的2型糖尿病合并轻、中度NPDR的患者60例。随机分为试验组和对照组,试验组患者采用二甲双胍+胰岛素联合利拉鲁肽强化控制血糖,对照组使用二甲双胍+胰岛素降低血糖。比较治疗前和治疗后3个月所有患者视网膜病变分期、黄斑区视网膜厚度和视网膜电图(electroretinogram,ERG)的振荡电位(oscillatory potentials,OPs)总波幅值。结果 治疗后3个月2组患者糖尿病视网膜病变(diabetic retinopathy DR)临床分期差异无统计学意义(P>0.05);试验组治疗前及治疗后黄斑区视网膜厚度分别是(284.98±28.54)μm、(278.84±27.98)μm,差异有统计学意义(P<0.01),对照组治疗前后及2组患者治疗后黄斑区视网膜厚度对比差异均无统计学意义(均为P>0.05)。试验组OPs总波幅治疗前后分别是(140.99±38.34)μV、(157.18±40.33)μV,差异有统计学意义(P=0.000);对照组OPs总波幅治疗前后分别是(140.80±38.60)μV、(133.76±43.29)μV,差异有统计学意义(P=0.015);治疗后试验组OPs总波幅较对照组高,差异有统计学意义(P=0.006)。结论 GLP-1类似物可以延缓轻、中度NPDR的进展,对其预后有着积极的作用。
Abstract:
Objective To investigate the clinical effect of glucagon-like peptide-1(GLP-1) analogues(liraglutide) on mild and moderate nonproliferative diabetic retinopathy (NPDR).Methods Sixty patients with type 2 diabetes mellitus and mild to moderate nonproliferative diabetic retinopathy (NPDR) were collected and randomly divided into experimental group and control group.And patients in the experimental group were treated with metformin plus insulin combined with liraglutide to control blood glucose,while metformin plus insulin for the patients in the control group.Then the staging of retinopathy,macular retinal thickness and total oscillatory potentials (OPs) of the full-field electroretinogram (F-ERG) of all patients before and at 3 months after treatment were compared and analyzed.Results There was no significant difference in the clinical staging of diabetic retinopathy(DR) between the two groups 3 months after treatment (P>0.05).The macular retinal thickness in the experimental group was (284.98±28.54)μm before treatment and(278.84±27.98)μm after treatment,and the difference was statistically significant(P<0.01).There was no significant difference in macular retinal thickness before and after treatment between the control group and the two groups after the treatment (all P>0.05).The total amplitude of Ops in the experimental group was (140.99±38.34)μV before treatment and (157.18+40.33)μV after treatment,and the difference was statistically significant (P<0.01).The total Ops amplitude of the control group before and after treatment was (140.80±38.60)μV and (133.76±43.29)μV,and the difference was statistically significant (P=0.015).The total amplitude of Ops in the experimental group after treatment was higher than that in the control group (P=0.006).Conclusion GLP-1 analogues can delay the progression of mild and moderate NPDR and have a positive effect on its prognosis.

参考文献/References:

[1] CHEN L R,YAO J P,ZHANG Y Z,ZHOU N,GAO B.Clinical significance of calcium hydroxide combined with GLP-1 in the treatment of diabetic retinopathy[J].Chin J Hosp Pharm,2017,37(15):1505-1508.
陈利荣,姚军平,张贻转,周宁,高波.羟苯磺酸钙联合GLP-1类似物治疗糖尿病视网膜病变的临床意义[J].中国医院药学杂志,2017,37(15):1505-1508.
[2] SIMO R,HERNANDEZ C.Neurodegeneration is an early event in diabetic retinopathy:therapeutic implications[J].Br J Ophthalmol,2012,96(10):1285-1290.
[3] LEI Y,ZHENG H H,CHEN X H,MEI X,CHEN M Z.Research advance in GLP-1 for the treatment of diabetic retinopathy[J].Rec Adv Ophthalmol,2017,37(12):1193-1196.
雷雨,郑宏华,陈小红,梅雪,陈梅珠.GLP-1防治糖尿病视网膜病变的研究进展[J].眼科新进展,2017,37(12):1193-1196.
[4] CAMPBELL J E,DRUCKER D J.Pharmacology,physiology,and mechanisms of incretin hormone action[J].Cell Metab,2013,17(6):819-837.
[5] PYKE C,HELLER R S,KIRK R K,ORSKOV C,REEDTZ-RUNGE S,KAASTRUP P,et al.GLP-1 receptor localization in monkey and human tissue:novel distribution revealed with extensively validated monoclonal antibody[J].Endocrinology,2014,155(4):1280-1290.
[6] HERNANDEZ C,BOGDANOV P,CORRALIZA L,GARCIA-RAMI-REZ M,SOLA-ADELL C,ARRANZ J A,et al.Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes[J].Diabetes,2016,65(1):172-187.
[7] HEINE R J,VAN G L F,JOHNS D,MIHM M J,WIDEL M H,BRODOWS R G,et al.Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes:a randomized trial[J].Ann Intern Med,2005,143(8):559-569.
[8] VARANASI A,CHAUDHURI A,DHINDSA S,ARORA A,LOHANO T,VORA M,et al.Durability of effects of exenatide treatment on glycaemic control,body weight,systolic blood pressure,Crp and triglyceride concentrations[J].Endocr Pract,2011,17(2):192-200.
[9] WILKINSON C P,FERRIS F L 3rd,KLEIN R E,LEE P P,AGARDH C D,DAVIS M,et al.Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J].Ophthalmology,2003,110(9):1677-1682.
[10] REDDY M A,ZHANG E,NATARAJAN R.Epigenetic mechanisms in diabetic complications and metabolic memory[J].Diabetologia,2015,58(3):443-455.
[11] BEREZIN A.Metabolic memory phenomenon in diabetes mellitus:Achieving and perspectives[J].Diabetes Metab Syndr,2016,10(2):176-183.
[12] HOLST J J.Glucagon-like peptide-1:from extract to agent.The claude bernard lecture,2005[J].Diabetologia,2006,49(2):253-260.
[13] GONCALVES A,LIN C M,MUTHUSAMY A,FONTES-RIBEIRO C,AMBROSIO A F,ABCOUWER S F,et al.Protective effect of a GLP-1 analog on ischemia-reperfusion induced blood-retinal barrier breakdown and inflammation[J].Invest Ophthalmol Vis Sci,2016,57(6):2584-2592.
[14] FAN Y C,LIU K,WANG Q P,RUAN Y Y,YE W,ZHANG Y.Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic goto-kakizaki rats [J].Exp Eye Res,2014,127(10):104-116.
[15] SHIN S,LE L J,EVERETT L J,GUPTA R,RAFIQ K,KAESTNER K H.CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse beta-cells[J].Mol Metab,2014,3(8):803-812.
[16] AGARWAL P,JINDAL A,SAINI V K,JINDAL S.Advances in diabetic retinopathy[J].IJEM,2014,18(6):772.
[17] BARBER A J.A new view of diabetic retinopathy:a neurodegenerative disease of the eye[J].Prog Neuropsychopharmacol Biol Psych,2003,27(2):283-290.
[18] SIMO R,HERNANDEZ C.Neurodegeneration in the diabetic eye:new insights and therapeutic perspectives[J].Trends Endocrinol Metab,2014,25(1):23-33.
[19] KANG P,LU H,WANG Z F,LI K J,YAO X.Comparative study of oscillatory potentials in electroretinogram and fluorescein fundus angiography in patients with diabetic retinopathy[J].Ophthalmol CHN,2010,19(4):283-284.
康平,路晖,王作芬,李凯军,姚雪.糖尿病视网膜病变患者视网膜电图震荡电位与荧光素眼底血管造影的对比研究[J].眼科,2010,19(4):283-284.
[20] KAWASAKI K.Preretinopathic changes in the oscillatory potential in diabetic retina:interpretation and significance[J].Nihon Ganka Gakkai Zasshi,1998,102(12):813-836.
[21] FANG Y H,ZHANG X D,LEI B.Research progress of oscillatory potentials in electroretinogram and its application in diabetic retinopathy[J].Chin J Ocul Fundus Dis,2013,29(1):106-108.
方晏红,张学东,雷博.视网膜电图震荡电位的研究进展及其在糖尿病视网膜病变中的应用[J].中华眼底病杂志,2013,29(1):106-108.
[22] VADALA M,ANASTASI M,LODATO G,CILLINO S.Electroretinographic oscillatory potentials in insulin-dependent diabetes patients:a long-term follow-up[J].Acta Ophthalmol Scand,2002,80(3):305-309.
[23] HANCOCK H A,KRAFT T W,OSCILLATOR Y.Potential analysis and ERGs of normal and diabetic rats[J].Invest Ophthalmol Vis Sci,2004,45(3):1002-1008.
[24] MARMOR M F,FULTON A B,HOLDER G E,MIYAKE Y,BRIGELL M,BACH M.ISCEV standard for full-field clinical electroretinography (2008 update)[J].Doc Ophthalmol,2009,118(1):69-77.
[25] LANG G E.Diabetic macular edema[J].Ophthalmologica,2012,227(suppl 1):21-29.

相似文献/References:

[1]曲申 徐蔚 孙小婷 毕燕龙 荣翱.Cirrus HD-OCT测量黄斑区视网膜厚度的可重复性研究[J].眼科新进展,2012,32(12):000.
[2]陈家欣,吴瑜瑜. 全视网膜光凝术对糖尿病视网膜病变视网膜神经纤维层及黄斑区视网膜的影响[J].眼科新进展,2015,35(4):380.[doi:10.13389/j.cnki.rao.2015.0103]
 CHEN Jia-Xin,WU Yu-Yu. Effects of panretinal photocoagulation on retinal nerve fiber layer and macular retina in patients with diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(7):380.[doi:10.13389/j.cnki.rao.2015.0103]

备注/Memo

备注/Memo:
福建省科技重点项目基金资助(编号:2016Y0067)
更新日期/Last Update: 2018-07-12